Compare CHD & RPRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CHD | RPRX |
|---|---|---|
| Founded | 1846 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Package Goods/Cosmetics | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 22.4B | 19.5B |
| IPO Year | 2014 | 2020 |
| Metric | CHD | RPRX |
|---|---|---|
| Price | $96.50 | $48.57 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 17 | 4 |
| Target Price | ★ $102.41 | $47.75 |
| AVG Volume (30 Days) | 1.8M | ★ 2.8M |
| Earning Date | 05-01-2026 | 05-07-2026 |
| Dividend Yield | 1.28% | ★ 1.95% |
| EPS Growth | ★ 27.43 | N/A |
| EPS | ★ 3.02 | 1.78 |
| Revenue | ★ $6,203,200,000.00 | $2,378,193,000.00 |
| Revenue This Year | $0.27 | $38.30 |
| Revenue Next Year | $3.65 | $4.80 |
| P/E Ratio | $31.85 | ★ $27.14 |
| Revenue Growth | 1.57 | ★ 5.06 |
| 52 Week Low | $81.33 | $31.58 |
| 52 Week High | $107.05 | $49.06 |
| Indicator | CHD | RPRX |
|---|---|---|
| Relative Strength Index (RSI) | 52.38 | 63.70 |
| Support Level | $94.88 | $35.32 |
| Resistance Level | $99.32 | N/A |
| Average True Range (ATR) | 1.95 | 1.00 |
| MACD | 0.16 | 0.08 |
| Stochastic Oscillator | 90.41 | 88.11 |
Church & Dwight is the leading global producer of baking soda. Its portfolio extends beyond its legacy category to include laundry products, cat litter, oral care, deodorant, and nasal care, all sold under the Arm & Hammer brand. Its brands also include Batiste, OxiClean, Vitafusion, Hero, and TheraBreath, which, together with Arm & Hammer, account for around 70% of its annual sales and profits. Most recently, the firm added Touchland and its hand sanitizer business to its fold. Even as it works to expand its product reach, Church & Dwight still derives around 80% of its sales from its home market in the US.
Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.